Wegovy (Semaglutide) vs. Trulicity (Dulaglutide): A Patient's Guide
Wegovy (semaglutide) and Trulicity (dulaglutide) are both GLP-1 receptor agonists, a class of medications that help with blood sugar control and can offer cardiovascular benefits. While they share similarities, their primary approved uses differ, leading to different considerations for patients and healthcare providers.
Side-by-Side Comparison
| Category | Semaglutide | Dulaglutide |
|---|---|---|
| Drug Class | GLP-1 Receptor Agonist | GLP-1 Receptor Agonist |
| Primary Approved Use | Weight loss in adults and children (12+) with obesity or overweight, and cardiovascular risk reduction in adults with established cardiovascular disease. | Type 2 diabetes management in adults and children (10+), and cardiovascular risk reduction in adults with type 2 diabetes. |
| Indications for Cardiovascular Benefit | To reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease. | To reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes. |
| Mechanism of Action | Semaglutide is a GLP-1 analogue that selectively binds to and activates the GLP-1 receptor. | Dulaglutide is a human GLP-1 receptor agonist that activates the GLP-1 receptor. |
| Key Warnings (Examples) | Acute Pancreatitis, Acute Gallbladder Disease. | Thyroid C-cell Tumors (Boxed Warning), Acute Pancreatitis. |
| When to Choose | A doctor might prefer Wegovy (semaglutide) if the primary goal is significant weight loss for adults or adolescents aged 12 and older with obesity or overweight. It is also indicated for cardiovascular risk reduction in adults with established cardiovascular disease, regardless of diabetes status. | A doctor might prefer Trulicity (dulaglutide) primarily for adults and children aged 10 and older with type 2 diabetes to improve blood sugar control. It also offers cardiovascular risk reduction specifically for adults with type 2 diabetes. |
| Side Effects | Both drugs share common side effects such as nausea, vomiting, diarrhea, and constipation, as they work similarly in the body. Both also carry warnings for acute pancreatitis. Trulicity has a boxed warning regarding thyroid C-cell tumors, while Wegovy has warnings about acute gallbladder disease. | |
| Cost | Neither semaglutide (Wegovy) nor dulaglutide (Trulicity) are currently available as generics. Both are brand-name medications and can be expensive, with costs varying based on insurance coverage and pharmacy pricing. |
Bottom Line
Wegovy and Trulicity are effective GLP-1 receptor agonists, but their main approved uses differ. Wegovy is primarily for weight management and cardiovascular risk reduction, while Trulicity is primarily for type 2 diabetes management and cardiovascular risk reduction in those with diabetes. Your doctor will help determine which medication is best suited for your specific health needs and goals.
Semaglutide Overview
Semaglutide is a once-weekly (or once-daily oral) GLP-1 receptor agonist that lowers blood sugar and reduces body weight by mimicking the natural gut hormone GLP-1. It is sold under three brand names — Ozempic (injectable, type 2 diabetes), Wegovy (injectable, weight management), and Rybelsus (oral tablet, type 2 diabetes) — all manufactured by Novo Nordisk. Clinical trials show it reduces HbA1c by up to 2.0 percentage points and body weight by up to 15% at the highest injectable dose.
Full Semaglutide guide →Dulaglutide Overview
Trulicity (dulaglutide) is a medication in a class called GLP-1 receptor agonists. It is used alongside diet and exercise to help adults and children aged 10 and older with type 2 diabetes manage their blood sugar levels. Additionally, for adults with type 2 diabetes who have heart disease or risk factors, Trulicity can help lower their risk of serious heart problems like heart attack or stroke.
Full Dulaglutide guide →Compare prices for Semaglutide and Dulaglutide
Check real-time pharmacy prices before you fill — free, no account needed.
Protect your muscle mass on GLP-1 medications
GLP-1 medications can cause up to 39% muscle loss alongside fat. Zova's AI-powered protocol — backed by Lancet Diabetes & Endocrinology research — reduces that to just 8.7% through leucine tracking and injection-day adaptive nutrition.
No credit card. No commitment.
Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.